SHIE.F Stock Overview
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Shield Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.019 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.019 |
| Beta | 0.84 |
| 1 Month Change | -36.00% |
| 3 Month Change | n/a |
| 1 Year Change | -74.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| SHIE.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.0% | -2.2% | -3.7% |
| 1Y | -74.9% | 11.6% | 20.5% |
Return vs Industry: SHIE.F underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: SHIE.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SHIE.F volatility | |
|---|---|
| SHIE.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SHIE.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SHIE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 27 | Greg Madison | www.shieldtherapeutics.com |
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc Fundamentals Summary
| SHIE.F fundamental statistics | |
|---|---|
| Market cap | US$14.38m |
| Earnings (TTM) | -US$48.88m |
| Revenue (TTM) | US$7.40m |
2.0x
P/S Ratio-0.3x
P/E RatioIs SHIE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHIE.F income statement (TTM) | |
|---|---|
| Revenue | US$7.40m |
| Cost of Revenue | US$4.08m |
| Gross Profit | US$3.31m |
| Other Expenses | US$52.19m |
| Earnings | -US$48.88m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.063 |
| Gross Margin | 44.77% |
| Net Profit Margin | -660.88% |
| Debt/Equity Ratio | 21.1% |
How did SHIE.F perform over the long term?
See historical performance and comparison